Inhibitors & Agonists

You can also try the following methods, and our professionals will serve you Customized Consultation

Cat. No.	Product Name	Field of Application
DC22981	A-37	A novel, potent and selective ALDH1A1 inhibitor with Ki of 300 nM and IC50 of 4.6 uM.
DC11799	G1T38	A novel, potent and selective inhibitor of CDK4/6 with biochemical IC50 of 1 nM and 2 nM for CDK4/cyclin D1 and CDK6/cyclin D3, respectively.
DC11800	G1T38 dihydrochloride	A novel, potent and selective inhibitor of CDK4/6 with biochemical IC50 of 1 nM and 2 nM for CDK4/cyclin D1 and CDK6/cyclin D3, respectively.
DC21033	Trilaciclib hydrochloride(G1T28) Featured	A novel, potent and selective inhibitor of CDK4/6 with biochemical IC50 of 1 nM and 4 nM for CDK4/cyclin D1 and CDK6/cyclin D3, respectively.
DC11804	IQS-019	A novel, potent inhibitor of most upstream tyrosine kinases in BCR signaling pathway, inhibits BCR kinases Lyn, Syk and Btk with IC50 of 0.15 uM, 1.6 uM and 2.1 uM, respectively.
DC11805	IQS-019 mesylate	A novel, potent inhibitor of most upstream tyrosine kinases in BCR signaling pathway, inhibits BCR kinases Lyn, Syk and Btk with IC50 of 0.15 uM, 1.6 uM and 2.1 uM, respectively.
DC20680	AS1604498	A novel, potent nicotinamide phosphoribosyl transferase (NAMPT) inhibitor with IC50 of 44 nM.
DC22533	Eleclazine hydrochloride Featured	A novel, potent, and selective inhibitor of Late sodium current (late INa) for treatment of long QT-3 syndrome (LQT-3), hypertrophic cardiomyopathy (HCM), and ventricular tachycardia–ventricular fibrillation (VT–VF).
DC11938	IPI-3063	A novel, potent, and selective p110δ PI3K inhibitor with IC50 of 0.1 nM in cell-based assays.
DC26067	BI1002494 trifluoroacetate	A novel, potent, and selective spleen tyrosine kinase (SYK) inhibitor with enzyme IC50 of 30 nM, cell IC50 of 7 nM (FcεR1-mediated histamine release in human monocyte-derived mast cells, in the presence of 0.1% albumin).
DC11778	PKC-IN-6c	A novel, potent, brain permeant PKC inhibitor with IC50 of 80 nM, without detectable binding to the estrogen receptor (Ki>10 uM).
DC20439	LXRβ agonist 17 Featured	LXRβ agonist 17 is a novel, potent, orally active liver X receptor β (LXRβ) agonist with Ki/EC50 of 3/21 nM, displays 27-fold selectivity over LXRα; also exhibits excellent selectivity against other nuclear hormone receptors (>3,000-fold); induces the expression of LXR target genes in vitro and in vivo.
DC22699	JNJ-26070109	A novel, potent, selective orally active CCK-2 receptor antagonist with pKi of 8.49 for hCCK2.
DC11970	KU675 Featured	A novel, second-generation C-terminal Hsp90 inhibitor with Kd of 191 and 726 uM for Hsp90α and Hsp90β, respectively.
DC11853	AC-73	A novel, specific CD147 inhibitor that can specifically disrupt CD147 dimerization, inhibits the motility and invasion of HCC cells (IC50=7-10 uM).
DC22991	IRES-C11	A novel, spectfic c-Myc IRES (internal ribosome entry site) function inhibitor that prevents binding of hnRNP A1 to the Myc IRES and specifically inhibits Myc IRES activity in MM cells.
DC21050	FN1-8 Featured	FN1-8 is a novel, synthetic small molecule that efficiently interferes with Gli/TAF9 interaction and downregulate Gli/TAF9-dependent transcriptional activity (at 15 uM); inhibits non-canonical Gli activation and acts downstream of the canonical Hh pathway; suppresses cancer cell proliferation in vitro and inhibits tumor growth in vivo.
DC10533	PKM2 inhibitor(compound 3k) Featured	A novle PKM2 inhibitor inhibitor.
DC21284	MK-0608	A nucleoside analogue that shows potent inhibition for replication of several mosquito-borne flaviviruses including DENV and ZIKV.
DC23940	NM107 Featured	NM-107, also known as 2'-C-Methylcytidine; 2'-C-MeC; 2-CMC; mCyd ; 2'CMeC; 2CMC, is a a potent and selective anti-viral drug. NM-107 showed activity to inhibit the replication of foot-and-mouth disease virus. NM-107 exerts potent anti-DENV activity in DENV subgenomic RNA replicon and infectious systems, with an IC50 value of 11.2±0.3μM. NM-107 may be a promising compound for the development of direct-acting antivirals against DENV infection.
DC22384	Abacavir sulfate	A nucleoside reverse transcriptase inhibitor (NRTI) that used to prevent and treat HIV/AIDS..
DC39815	Tafluprost Featured	Tafluprost(AFP-168) is an anti-glaucoma prostaglandin (PG) analog.A number of 17-phenyl trinor PGF2α derivatives have been approved for the treatment of glaucoma.1,2,3,4 Of these, the ones wherein the 13,14-double bond has been hydrogenated retain relatively good potency.
DC22709	LY3027788	A orally active prodrug of LY3020371, which is a potent, selective metabotropic glutamate 2/3 receptor (mGlu2/3) antagonist with Ki of 5.3 and 2.5 nM, respectively.
DC11882	HJC0416	A orally bioavailable small-molecule STAT3 inhibitor.
DC22989	BMS-204493 Featured	A pan-RAR inverse agonist that blocks RARα activity with IC50 of 114 nM.
DC23094	TRAP-6 Featured	A PAR1 peptide fragment (residues 42-47) that acts as a PAR1 agonist.
DC22372	Dexpramipexole Featured	A partial/full agonist of dopamine receptor with Ki of 3.9/2.2/0.5/5.1 nM for D2S/D2L/D3/D4, respeectively.
DC22373	Dexpramipexole dihydrochloride Featured	Dexpramipexole 2Hcl(KNS-760704), also known as R-(+)-Pramipexole, is a neuroprotective agent and weak non-ergoline dopamine agonist. IC50 Value:Target: Dopamine ReceptorDexpramipexole has been found to have neuroprotective effects and is being investigated for treatment of amyotrophic lateral sclerosis (ALS). Dexpramipexole reduces mitochondrial reactive oxygen species (ROS) production, inhibits the activation of apoptotic pathways, and increase cell survival in response to a variety of neurotoxins and β-amyloid neurotoxicity. Compared to the S-(-) isomer, Dexpramipexole has much lower dopamine agonist activity.
DC8496	CTP 518(Atazanavir, deuterated)	A partially dueterated analog of Atazanavir, an oral HIV protease inhibitor; A deuterium-containing medicine with improved ADME properties; Compound 120 showed an approximately 50% increase in half life compared with Atazanavir.
DC22356	Capreomycin sulfate	A peptide antibiotic, commonly grouped with the aminoglycosides, which is given in combination with other antibiotics for MDR-tuberculosis. .

<Prev1...63 64 65 66 67...1297 Next>

Inhibitors & Agonists

Customized Consultation X

Your information is safe with us. * Required Fields.